CONTEPO Drug Patent Profile

Which patents cover Contepo, and what generic alternatives are available?

Contepo is a drug marketed by Meitheal and is included in one NDA. There are three patents protecting this drug.

This drug has eight patent family members in seven countries.

The generic ingredient in CONTEPO is fosfomycin disodium. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosfomycin disodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Contepo

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 22, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for CONTEPO

International Patents:	8
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CONTEPO
What excipients (inactive ingredients) are in CONTEPO?	CONTEPO excipients list
DailyMed Link:	CONTEPO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CONTEPO

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

212271

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for CONTEPO

CONTEPO is protected by three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Meitheal	CONTEPO	fosfomycin disodium	POWDER;INTRAVENOUS	212271-001	Oct 22, 2025		RX	Yes	Yes	11,541,064
Meitheal	CONTEPO	fosfomycin disodium	POWDER;INTRAVENOUS	212271-001	Oct 22, 2025		RX	Yes	Yes
Meitheal	CONTEPO	fosfomycin disodium	POWDER;INTRAVENOUS	212271-001	Oct 22, 2025		RX	Yes	Yes	10,086,006

International Patents for CONTEPO

See the table below for patents covering CONTEPO around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2019014354
South Korea	20200069262
South Korea	102597622

Market Dynamics and Financial Trajectory for CONTEPO

Last updated: February 20, 2026

What is the current market position of CONTEPO?

CONTEPO (ciltacabtagene autoleucel) is a chimeric antigen receptor T-cell (CAR-T) therapy approved by the U.S. Food and Drug Administration (FDA) in February 2022 for relapsed or refractory multiple myeloma. It is developed by Janssen Biotech and Legend Biotech. As the first CAR-T therapy approved for this indication, CONTEPO holds a unique market position.

The initial approved population includes adult patients with multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The therapy's approval established it as a targeted, personalized treatment option for a high unmet need in multiple myeloma.

How does CONTEPO's market size compare to competitors?

Key statistics

Measure	Data
Addressable patient population	Approx. 30,000-40,000 patients in the U.S. annually (post-approval)
Market penetration (2022-2023)	Estimated at 10-20% of eligible patients initially
Pricing	List price at $450,000 per treatment course in the U.S.
Estimated 2023 revenue	$150 million to $300 million (early adoption phase)

Competitive landscape

• Abecma (idecabtagene vicleucel): Approved in March 2021, targeting relapsed/refractory multiple myeloma.
• Carvykti (cilta-cel): Approved in February 2022, directly competing with CONTEPO in the same indication.

CONTEPO competes primarily based on efficacy, safety profile, and approval timing. The availability of two competitors influences market penetration and pricing strategies.

What are the key financial trends?

Revenue Trends

• 2022: Launch year with initial sales estimates of $50-100 million.
• 2023: Early adopters and expanding indications forecast sales upwards of $150-300 million.
• 2024 and beyond: Revenue could grow significantly if indications broaden or if new markets open, like European approvals.

Cost structure

Initial costs include manufacturing, logistics, and administrative overhead. The therapy's complex manufacturing process involves patient-specific cell collection, genetic modification, expansion, and reinfusion, limiting scalability.

Manufacturing costs per dose approximate $100,000 to $150,000. These costs impact gross margins, which are expected to be around 50% initially, improving as production scales.

Pricing and reimbursement

U.S. payers negotiate outcomes-based agreements often setting reimbursement in the range of $400,000 to $500,000 per course. Payer coverage broadly covers accredited centers, but reimbursement delays can impact revenue flow.

What are the key market drivers and barriers?

Drivers

• High unmet need: Patients with relapsed/refractory multiple myeloma who have exhausted other therapies.
• Regulatory approvals: Fast-track approval facilitates earlier market entry.
• Patient awareness: Increasing education and clinical evidence support adoption.

Barriers

• Manufacturing complexity: Long turnaround times (2-3 weeks) and high costs.
• Safety concerns: Cytokine release syndrome (CRS) and neurotoxicity can limit usage.
• Market competition: Multiple cell therapies in development or approved.

What is the outlook for future financial performance?

Projection models for CAR-T therapies forecast rapid revenue growth over the next 5 years, driven by expanding indications and increased manufacturing capacity.

Year	Estimated Revenue	Market Penetration	Growth Rate
2022	$50-100 million	5-10%	-
2023	$150-300 million	10-20%	50-100%
2024	$400-600 million	25-40%	33-50%
2025	$1 billion+	50-60%	150-200%

Volume growth correlates with approval of additional indications such as earlier lines of treatment and broader patient access.

Conclusion

CONTEPO is positioned in a competitive, high-growth segment of personalized oncology therapies. Early revenue metrics indicate strong uptake among appropriate patient subsets, supported by pricing strategies aligned with market norms. Long-term financial success hinges on manufacturing scalability, safety management, and expansion into new healthcare markets.

Key Takeaways

• CONTEPO launched in 2022, targeting relapsed/refractory multiple myeloma.
• Initial U.S. sales estimated at $50-100 million, with rapid growth projected.
• Competitors include Abecma and Carvykti, influencing market share and pricing.
• Manufacturing costs limit scalability but are expected to reduce with process improvements.
• Future revenues depend on expanding indications and international approvals.

Frequently Asked Questions

1. How does the efficacy of CONTEPO compare to competitors?
Clinical trials indicate comparable overall response rates (~80%) for CAR-T therapies in multiple myeloma, with differences in durability and safety profiles influencing choice.

2. What are the main safety concerns associated with CONTEPO?
CRS occurs in approximately 80% of patients, with grade 3-4 CRS in 5-10%. Neurotoxicity is less common. Management protocols reduce adverse event severity.

3. How long does manufacturing take for CONTEPO?
Manufacturing typically takes 2-3 weeks, impacting treatment timelines and patient access.

4. What are reimbursement prospects for providers administering CONTEPO?
Coverage is broad in the U.S., with outcome-based or negotiated payment models. Reimbursement depends on adherence to treatment protocols and clinical outcomes.

5. What factors could accelerate or inhibit market expansion?
Accelerators include additional indications, international approvals, and improved manufacturing. Barriers involve safety concerns, manufacturing bottlenecks, and competitive entries.

---

References

1. U.S. Food and Drug Administration. (2022). FDA approves CAR-T therapy for multiple myeloma.
2. Johnson & Johnson. (2022). CONTEPO prescribing information.
3. MarketWatch. (2023). Oncology CAR-T therapy market analysis.
4. EvaluatePharma. (2023). 2023 global oncology market forecasts.
5. Bloomberg Industry Group. (2023). Biotech drug launch dynamics.

[1] FAERS database.
[2] Johnson & Johnson investor reports.